Comparison of the Predictive Capacity of Oxygenation Parameters, Oxygenation Indices, and CURB-65 to Mortality, Mechanical Ventilation, and Vasopressor Support in Community-Acquired Pneumonia at Different Altitudes.
Eduardo Tuta-Quintero, Alirio R Bastidas, Angelica Mora, Luis F Reyes, Laura E Bello, Alejandra P Nonzoque, Laura D Saza, Natalia Trujillo, Jenifer C Arias, Paola Mejía Martinez, Daniel Osorio, Paola Narváez, Laura Perdomo, Luis Vargas, María Pérez, Jesus Rubiano, Paula Pinillos, Juan Naranjo, Angela María Martínez
{"title":"Comparison of the Predictive Capacity of Oxygenation Parameters, Oxygenation Indices, and CURB-65 to Mortality, Mechanical Ventilation, and Vasopressor Support in Community-Acquired Pneumonia at Different Altitudes.","authors":"Eduardo Tuta-Quintero, Alirio R Bastidas, Angelica Mora, Luis F Reyes, Laura E Bello, Alejandra P Nonzoque, Laura D Saza, Natalia Trujillo, Jenifer C Arias, Paola Mejía Martinez, Daniel Osorio, Paola Narváez, Laura Perdomo, Luis Vargas, María Pérez, Jesus Rubiano, Paula Pinillos, Juan Naranjo, Angela María Martínez","doi":"10.1155/carj/9378618","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Populations residing at high altitudes display distinct physiological adaptations that are essential for understanding respiratory diseases. However, there is limited research on how these adaptations affect the assessment and prognosis of community-acquired pneumonia (CAP). <b>Methods:</b> A prognostic validation nested within a retrospective cohort was conducted on subjects with pneumonia admitted to two high-complexity institutions in Colombia at different altitudes above sea level. The receiver operating characteristic (ROC) curves were calculated for SaO<sub>2</sub>, PaO<sub>2</sub>, SpO<sub>2</sub>, A-a O<sub>2</sub> gradient, a-A index, PaO<sub>2</sub>/FiO<sub>2</sub>, SpO<sub>2</sub>/FiO<sub>2</sub>, and the CURB-65 score to predict 30-day mortality, requirement for invasive mechanical ventilation (IMV), and need for vasopressor support. <b>Results:</b> 3467 were selected for analysis, with 73.7% (2557/3467) residing at high altitudes and 26.2% (910/3467) at low altitudes. The CURB-65 score ≥ 2 showed a performance in predicting mortality of 0.707 (95% CI: 0.653-0.761; <i>p</i> < 0.001) at low altitudes and 0.737 (95% CI: 0.709-0.765; <i>p</i> < 0.001) at high altitudes. The PaO<sub>2</sub>/FiO<sub>2</sub> ≤ 300 showed a performance in predicting the need for IMV and vasopressor support of 0.734 (95% CI: 0.685-0.783; <i>p</i> < 0.001) and 0.724 (0.674-0.775; <i>p</i> < 0.001) at high altitudes, respectively. The SpO<sub>2</sub>/FiO<sub>2</sub> ≤ 350 showed a performance in predicting the need for IMV of 0.679 (0.507-0.85; <i>p</i> < 0.001) at low altitudes. The A-a O<sub>2</sub> gradient ≥ 10 showed a performance in predicting the need for vasopressor support of 0.686 (95% CI: 0.537-0.835; <i>p</i>=0.06) at low altitudes. <b>Conclusion:</b> In patients with CAP at altitudes above 2500 m above sea level, PaO<sub>2</sub>/FiO<sub>2</sub>, SpO<sub>2</sub>/FiO<sub>2</sub>, and the A-a O<sub>2</sub> gradient show a greater predictive capacity for 30-day mortality, need for IMV, and vasopressor requirements. The CURB-65 score showed a good predictive performance.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2025 ","pages":"9378618"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991769/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian respiratory journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/carj/9378618","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Populations residing at high altitudes display distinct physiological adaptations that are essential for understanding respiratory diseases. However, there is limited research on how these adaptations affect the assessment and prognosis of community-acquired pneumonia (CAP). Methods: A prognostic validation nested within a retrospective cohort was conducted on subjects with pneumonia admitted to two high-complexity institutions in Colombia at different altitudes above sea level. The receiver operating characteristic (ROC) curves were calculated for SaO2, PaO2, SpO2, A-a O2 gradient, a-A index, PaO2/FiO2, SpO2/FiO2, and the CURB-65 score to predict 30-day mortality, requirement for invasive mechanical ventilation (IMV), and need for vasopressor support. Results: 3467 were selected for analysis, with 73.7% (2557/3467) residing at high altitudes and 26.2% (910/3467) at low altitudes. The CURB-65 score ≥ 2 showed a performance in predicting mortality of 0.707 (95% CI: 0.653-0.761; p < 0.001) at low altitudes and 0.737 (95% CI: 0.709-0.765; p < 0.001) at high altitudes. The PaO2/FiO2 ≤ 300 showed a performance in predicting the need for IMV and vasopressor support of 0.734 (95% CI: 0.685-0.783; p < 0.001) and 0.724 (0.674-0.775; p < 0.001) at high altitudes, respectively. The SpO2/FiO2 ≤ 350 showed a performance in predicting the need for IMV of 0.679 (0.507-0.85; p < 0.001) at low altitudes. The A-a O2 gradient ≥ 10 showed a performance in predicting the need for vasopressor support of 0.686 (95% CI: 0.537-0.835; p=0.06) at low altitudes. Conclusion: In patients with CAP at altitudes above 2500 m above sea level, PaO2/FiO2, SpO2/FiO2, and the A-a O2 gradient show a greater predictive capacity for 30-day mortality, need for IMV, and vasopressor requirements. The CURB-65 score showed a good predictive performance.
期刊介绍:
Canadian Respiratory Journal is a peer-reviewed, Open Access journal that aims to provide a multidisciplinary forum for research in all areas of respiratory medicine. The journal publishes original research articles, review articles, and clinical studies related to asthma, allergy, COPD, non-invasive ventilation, therapeutic intervention, lung cancer, airway and lung infections, as well as any other respiratory diseases.